Heron Therapeutics (HRTX) Misses Q3 EPS by 9c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.10), $0.09 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $38.2 million versus the consensus estimate of $39.49 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• Apogee Therapeutics (APGE) call put ratio 1.1 calls to 1 put into share price up before the bell
• Lineage (LINE) call put ratio 1.3 calls to 1 put